Karachi, March 3, 2026 – The Board of Directors of Citi Pharma Limited has approved the initiation of an Initial Public Offering (IPO) of its wholly owned subsidiary, Citi Veterinary Pharma Limited, aiming to raise up to Rs2 billion.
In a communication submitted to the Pakistan Stock Exchange (PSX), the company announced that the IPO process has been formally authorized as part of its expansion and diversification strategy.
IPO to Support Veterinary Pharma Expansion
Citi Veterinary Pharma Limited has been established as a dedicated entity focused on the manufacturing of veterinary active pharmaceutical ingredients (APIs) and pharmaceutical products for the local market. The planned IPO will help the company secure funding between Rs1 billion and Rs2 billion to strengthen production capacity, expand operations, and enhance its footprint in Pakistan’s growing veterinary healthcare segment.
The Board has also approved the appointment of K-Trade Securities Limited as the consultant for the IPO process, with the objective of listing the subsidiary at the earliest possible date.
Strategic Diversification Move
The move marks a significant milestone for Citi Pharma Limited as it seeks to diversify its revenue streams within the broader pharmaceutical sector. By entering the veterinary-focused API and pharmaceutical manufacturing segment through a separate listed entity, the company aims to capitalize on increasing demand for animal healthcare products in Pakistan.
Citi Pharma has projected that it expects to generate approximately Rs1.5 billion in revenue during FY26 through the trading of veterinary products, reflecting strong growth potential in the segment.
The IPO of Citi Veterinary Pharma Limited is anticipated to attract investor interest as the company positions itself in a niche yet expanding area of the pharmaceutical industry.